Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –– Topline data for ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. UBX1325 met safety and efficacy endpoints at 24 weeks in ...

LONDON--(BUSINESS WIRE)--The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of more than 1% during the forecast period, according to the latest market research ...